 Leigh Perreault
Concepts (337)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prediabetic State | 24 | 2024 | 243 | 6.420 |
Why?
| | Diabetes Mellitus, Type 2 | 50 | 2024 | 2516 | 4.690 |
Why?
| | Insulin Resistance | 34 | 2025 | 1232 | 3.980 |
Why?
| | Obesity | 32 | 2026 | 3057 | 3.360 |
Why?
| | Hypoglycemic Agents | 23 | 2023 | 1379 | 2.860 |
Why?
| | Weight Loss | 18 | 2026 | 832 | 2.480 |
Why?
| | Blood Glucose | 31 | 2023 | 2312 | 2.370 |
Why?
| | Weight Reduction Programs | 4 | 2026 | 135 | 2.170 |
Why?
| | Muscle, Skeletal | 22 | 2025 | 1792 | 2.120 |
Why?
| | Cardiovascular Diseases | 15 | 2020 | 2134 | 1.920 |
Why?
| | Primary Health Care | 8 | 2026 | 1710 | 1.740 |
Why?
| | Insulin | 20 | 2024 | 2501 | 1.680 |
Why?
| | Sphingolipids | 7 | 2024 | 83 | 1.580 |
Why?
| | Diabetes Mellitus | 11 | 2023 | 1092 | 1.510 |
Why?
| | Triglycerides | 11 | 2024 | 512 | 1.490 |
Why?
| | Glucose Intolerance | 8 | 2020 | 142 | 1.370 |
Why?
| | Benzhydryl Compounds | 3 | 2017 | 82 | 1.360 |
Why?
| | Diabetic Angiopathies | 3 | 2017 | 254 | 1.360 |
Why?
| | Diglycerides | 6 | 2024 | 59 | 1.230 |
Why?
| | Diabetes Complications | 2 | 2019 | 220 | 1.050 |
Why?
| | Overweight | 7 | 2022 | 606 | 1.010 |
Why?
| | Glucosides | 2 | 2017 | 55 | 1.010 |
Why?
| | Life Style | 12 | 2020 | 475 | 0.940 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2023 | 145 | 0.940 |
Why?
| | Exercise | 12 | 2025 | 2193 | 0.890 |
Why?
| | Metformin | 13 | 2023 | 315 | 0.860 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 2023 | 7 | 0.810 |
Why?
| | Glucose Tolerance Test | 15 | 2021 | 360 | 0.800 |
Why?
| | Adipose Tissue | 5 | 2025 | 651 | 0.790 |
Why?
| | Anti-Obesity Agents | 2 | 2024 | 64 | 0.790 |
Why?
| | Adult | 57 | 2025 | 40262 | 0.780 |
Why?
| | Humans | 99 | 2026 | 144261 | 0.770 |
Why?
| | Glucose Clamp Technique | 11 | 2024 | 199 | 0.760 |
Why?
| | Cannabidiol | 1 | 2025 | 136 | 0.760 |
Why?
| | Goals | 2 | 2021 | 180 | 0.740 |
Why?
| | Dronabinol | 1 | 2025 | 247 | 0.720 |
Why?
| | Middle Aged | 47 | 2025 | 35762 | 0.710 |
Why?
| | Nutrition Therapy | 1 | 2022 | 36 | 0.690 |
Why?
| | Marijuana Use | 1 | 2025 | 213 | 0.680 |
Why?
| | Male | 63 | 2026 | 72035 | 0.670 |
Why?
| | Body Mass Index | 13 | 2025 | 2420 | 0.670 |
Why?
| | Liver | 4 | 2014 | 1884 | 0.660 |
Why?
| | Female | 68 | 2026 | 77976 | 0.650 |
Why?
| | Health Equity | 1 | 2023 | 129 | 0.650 |
Why?
| | Primary Care Nursing | 1 | 2019 | 4 | 0.620 |
Why?
| | Hyperglycemia | 4 | 2014 | 374 | 0.610 |
Why?
| | Weight Gain | 5 | 2025 | 556 | 0.580 |
Why?
| | Lipid Metabolism | 5 | 2025 | 525 | 0.570 |
Why?
| | Obesity Management | 1 | 2018 | 7 | 0.570 |
Why?
| | Peripheral Vascular Diseases | 1 | 2019 | 103 | 0.570 |
Why?
| | Insulin, Long-Acting | 1 | 2019 | 65 | 0.560 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 113 | 0.550 |
Why?
| | Microvessels | 1 | 2019 | 98 | 0.550 |
Why?
| | Awareness | 1 | 2019 | 106 | 0.540 |
Why?
| | Cannabis | 1 | 2025 | 509 | 0.540 |
Why?
| | Fasting | 4 | 2020 | 276 | 0.530 |
Why?
| | Policy | 1 | 2018 | 146 | 0.510 |
Why?
| | Ceramides | 5 | 2024 | 116 | 0.510 |
Why?
| | Risk Management | 1 | 2017 | 84 | 0.500 |
Why?
| | Precision Medicine | 1 | 2021 | 456 | 0.500 |
Why?
| | Incretins | 2 | 2021 | 21 | 0.490 |
Why?
| | Risk Factors | 19 | 2023 | 10699 | 0.490 |
Why?
| | Rest | 2 | 2017 | 124 | 0.480 |
Why?
| | Choristoma | 1 | 2015 | 21 | 0.460 |
Why?
| | Sleep Deprivation | 5 | 2021 | 206 | 0.440 |
Why?
| | Insulin-Secreting Cells | 2 | 2010 | 387 | 0.430 |
Why?
| | Inflammation | 1 | 2025 | 2877 | 0.400 |
Why?
| | Sarcolemma | 3 | 2024 | 38 | 0.390 |
Why?
| | Glucose | 4 | 2023 | 1046 | 0.380 |
Why?
| | Phenols | 1 | 2013 | 114 | 0.370 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1050 | 0.370 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1705 | 0.360 |
Why?
| | Colorado | 5 | 2026 | 4562 | 0.360 |
Why?
| | Lipids | 4 | 2024 | 700 | 0.360 |
Why?
| | Aged | 18 | 2025 | 25850 | 0.340 |
Why?
| | Physical Endurance | 5 | 2020 | 278 | 0.340 |
Why?
| | Fenofibrate | 1 | 2011 | 27 | 0.330 |
Why?
| | Athletes | 7 | 2024 | 417 | 0.320 |
Why?
| | Hypolipidemic Agents | 1 | 2011 | 86 | 0.320 |
Why?
| | Glucagon-Like Peptides | 2 | 2022 | 70 | 0.320 |
Why?
| | Phosphatidylcholines | 2 | 2024 | 130 | 0.310 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 46 | 0.310 |
Why?
| | Palmitates | 1 | 2009 | 21 | 0.310 |
Why?
| | Pyrazines | 1 | 2010 | 92 | 0.300 |
Why?
| | Cross-Sectional Studies | 9 | 2024 | 5813 | 0.300 |
Why?
| | Hospitalization | 1 | 2019 | 2424 | 0.290 |
Why?
| | Triazoles | 1 | 2010 | 184 | 0.290 |
Why?
| | Energy Metabolism | 4 | 2021 | 935 | 0.280 |
Why?
| | Young Adult | 13 | 2025 | 13990 | 0.280 |
Why?
| | Biomarkers | 8 | 2023 | 4254 | 0.270 |
Why?
| | Electronic Health Records | 2 | 2026 | 1169 | 0.260 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2017 | 29 | 0.260 |
Why?
| | Sleep | 4 | 2021 | 901 | 0.260 |
Why?
| | Risk Reduction Behavior | 3 | 2023 | 225 | 0.260 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 314 | 0.250 |
Why?
| | Markov Chains | 2 | 2018 | 126 | 0.250 |
Why?
| | Sex Characteristics | 3 | 2021 | 789 | 0.250 |
Why?
| | Absenteeism | 2 | 2018 | 52 | 0.250 |
Why?
| | Double-Blind Method | 5 | 2024 | 2025 | 0.240 |
Why?
| | Health Services | 2 | 2018 | 114 | 0.240 |
Why?
| | Sex Factors | 5 | 2018 | 2096 | 0.240 |
Why?
| | Adiponectin | 3 | 2018 | 243 | 0.230 |
Why?
| | Muscle Fibers, Skeletal | 3 | 2024 | 214 | 0.220 |
Why?
| | Remission Induction | 3 | 2019 | 306 | 0.220 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5389 | 0.220 |
Why?
| | Pilot Projects | 2 | 2021 | 1867 | 0.220 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2022 | 653 | 0.210 |
Why?
| | Carnitine | 2 | 2024 | 90 | 0.210 |
Why?
| | Circadian Rhythm | 3 | 2019 | 513 | 0.210 |
Why?
| | Lipogenesis | 2 | 2017 | 62 | 0.200 |
Why?
| | Dietary Fats | 3 | 2020 | 313 | 0.200 |
Why?
| | Lipoprotein Lipase | 1 | 2004 | 56 | 0.200 |
Why?
| | Cross-Over Studies | 1 | 2026 | 600 | 0.200 |
Why?
| | Hyperinsulinism | 1 | 2024 | 113 | 0.200 |
Why?
| | Physical Exertion | 1 | 2004 | 207 | 0.190 |
Why?
| | Oxidation-Reduction | 4 | 2024 | 1084 | 0.190 |
Why?
| | Healthy Lifestyle | 1 | 2023 | 37 | 0.190 |
Why?
| | Computer Simulation | 2 | 2018 | 1025 | 0.180 |
Why?
| | Diet, Reducing | 3 | 2017 | 91 | 0.180 |
Why?
| | Energy Intake | 4 | 2021 | 499 | 0.180 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1312 | 0.180 |
Why?
| | Biopsy | 3 | 2018 | 1075 | 0.180 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1264 | 0.180 |
Why?
| | Cluster Analysis | 1 | 2023 | 519 | 0.170 |
Why?
| | Endpoint Determination | 2 | 2019 | 83 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2024 | 2026 | 0.170 |
Why?
| | Nephrology | 1 | 2022 | 60 | 0.170 |
Why?
| | Prevalence | 2 | 2019 | 2815 | 0.170 |
Why?
| | Glucose Transporter Type 4 | 1 | 2021 | 38 | 0.170 |
Why?
| | Cytosol | 2 | 2020 | 227 | 0.170 |
Why?
| | Body Weight | 4 | 2024 | 976 | 0.160 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 264 | 0.160 |
Why?
| | Risk Adjustment | 1 | 2020 | 85 | 0.160 |
Why?
| | Endocrinologists | 1 | 2020 | 11 | 0.160 |
Why?
| | New Zealand | 1 | 2019 | 54 | 0.150 |
Why?
| | Cytosine | 1 | 2019 | 51 | 0.150 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 266 | 0.150 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 132 | 0.150 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2019 | 158 | 0.140 |
Why?
| | Fatty Liver | 1 | 2021 | 251 | 0.140 |
Why?
| | Liraglutide | 1 | 2019 | 32 | 0.140 |
Why?
| | Exercise Test | 3 | 2015 | 634 | 0.140 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.140 |
Why?
| | Retinal Diseases | 1 | 2019 | 99 | 0.140 |
Why?
| | Postprandial Period | 1 | 2019 | 115 | 0.140 |
Why?
| | Quinolizines | 1 | 1997 | 9 | 0.140 |
Why?
| | Adolescent | 8 | 2023 | 22281 | 0.130 |
Why?
| | Drug Combinations | 1 | 2019 | 390 | 0.130 |
Why?
| | United States | 9 | 2023 | 15876 | 0.130 |
Why?
| | Nausea | 1 | 1997 | 111 | 0.130 |
Why?
| | Antiemetics | 1 | 1997 | 49 | 0.130 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 194 | 0.130 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 244 | 0.130 |
Why?
| | Cytokines | 1 | 2025 | 2061 | 0.130 |
Why?
| | Health Resources | 1 | 2018 | 129 | 0.130 |
Why?
| | Vomiting | 1 | 1997 | 130 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2023 | 847 | 0.120 |
Why?
| | Hysterectomy | 1 | 1997 | 137 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2917 | 0.120 |
Why?
| | Odds Ratio | 1 | 2019 | 1072 | 0.120 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 316 | 0.120 |
Why?
| | Patient-Centered Care | 1 | 2021 | 540 | 0.120 |
Why?
| | Patient Participation | 1 | 2019 | 429 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 940 | 0.120 |
Why?
| | Blotting, Western | 2 | 2016 | 1187 | 0.120 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 76 | 0.120 |
Why?
| | Phenotype | 1 | 2024 | 3157 | 0.120 |
Why?
| | Eating | 2 | 2021 | 389 | 0.120 |
Why?
| | Research Design | 2 | 2019 | 1129 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 623 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 2 | 2024 | 576 | 0.110 |
Why?
| | Kidney Diseases | 1 | 2019 | 425 | 0.110 |
Why?
| | Treatment Outcome | 6 | 2021 | 11643 | 0.110 |
Why?
| | Exercise Therapy | 2 | 2017 | 467 | 0.110 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 218 | 0.110 |
Why?
| | Patient Compliance | 1 | 2019 | 585 | 0.110 |
Why?
| | Income | 1 | 2015 | 199 | 0.100 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 97 | 0.100 |
Why?
| | Somatostatin | 1 | 2014 | 51 | 0.100 |
Why?
| | Hypoglycemia | 1 | 2019 | 477 | 0.100 |
Why?
| | Logistic Models | 1 | 2019 | 2104 | 0.100 |
Why?
| | Smoking | 2 | 2012 | 1468 | 0.100 |
Why?
| | Indoles | 1 | 1997 | 501 | 0.100 |
Why?
| | Pneumonia | 1 | 2019 | 630 | 0.100 |
Why?
| | Employment | 1 | 2015 | 185 | 0.100 |
Why?
| | Fructose | 1 | 2014 | 129 | 0.100 |
Why?
| | Recovery of Function | 2 | 2015 | 706 | 0.100 |
Why?
| | Health Personnel | 1 | 2019 | 742 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2014 | 113 | 0.100 |
Why?
| | Consensus | 3 | 2020 | 488 | 0.100 |
Why?
| | Cost of Illness | 1 | 2015 | 319 | 0.090 |
Why?
| | C-Reactive Protein | 1 | 2015 | 416 | 0.090 |
Why?
| | Oxygen Consumption | 4 | 2016 | 724 | 0.090 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 54 | 0.090 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 402 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2016 | 582 | 0.090 |
Why?
| | Homeostasis | 1 | 2016 | 640 | 0.090 |
Why?
| | Qualitative Research | 1 | 2019 | 1659 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2019 | 8243 | 0.090 |
Why?
| | Adult Children | 1 | 2011 | 26 | 0.090 |
Why?
| | Placebos | 2 | 2009 | 192 | 0.090 |
Why?
| | Prospective Studies | 3 | 2019 | 7970 | 0.080 |
Why?
| | Mitochondria | 1 | 2018 | 983 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1559 | 0.080 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.080 |
Why?
| | Diabetes, Gestational | 1 | 2015 | 321 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3313 | 0.080 |
Why?
| | Health Behavior | 2 | 2023 | 782 | 0.080 |
Why?
| | Sitagliptin Phosphate | 1 | 2010 | 31 | 0.080 |
Why?
| | Family Health | 1 | 2011 | 191 | 0.080 |
Why?
| | Comorbidity | 1 | 2015 | 1646 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1409 | 0.080 |
Why?
| | Metabolomics | 1 | 2015 | 726 | 0.080 |
Why?
| | Longevity | 1 | 2011 | 173 | 0.080 |
Why?
| | Mitochondria, Muscle | 2 | 2021 | 121 | 0.070 |
Why?
| | C-Peptide | 1 | 2010 | 186 | 0.070 |
Why?
| | Quality of Life | 3 | 2019 | 3166 | 0.070 |
Why?
| | Disease Progression | 3 | 2024 | 2840 | 0.070 |
Why?
| | Menopause | 1 | 2011 | 319 | 0.070 |
Why?
| | Leisure Activities | 1 | 2008 | 30 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1759 | 0.070 |
Why?
| | Delphi Technique | 2 | 2019 | 329 | 0.060 |
Why?
| | Body Composition | 1 | 2011 | 704 | 0.060 |
Why?
| | Risk Assessment | 3 | 2015 | 3637 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 2111 | 0.060 |
Why?
| | Fibrinogen | 2 | 2018 | 176 | 0.060 |
Why?
| | Cohort Studies | 4 | 2021 | 5935 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1533 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2012 | 3842 | 0.060 |
Why?
| | Regression Analysis | 2 | 2019 | 998 | 0.060 |
Why?
| | Postoperative Complications | 1 | 1997 | 2916 | 0.050 |
Why?
| | Mass Screening | 1 | 2013 | 1332 | 0.050 |
Why?
| | Aging | 1 | 2015 | 1964 | 0.050 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 114 | 0.050 |
Why?
| | Health Expenditures | 1 | 1986 | 194 | 0.050 |
Why?
| | Incidence | 3 | 2019 | 2870 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1782 | 0.050 |
Why?
| | Hormones | 1 | 2004 | 134 | 0.050 |
Why?
| | Prognosis | 2 | 2023 | 4278 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2019 | 17009 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2003 | 140 | 0.050 |
Why?
| | Depression | 1 | 2012 | 1533 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2023 | 68 | 0.050 |
Why?
| | Parents | 1 | 2011 | 1401 | 0.050 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 216 | 0.050 |
Why?
| | Alcohol Drinking | 1 | 2009 | 812 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5988 | 0.050 |
Why?
| | Lactic Acid | 1 | 2003 | 302 | 0.040 |
Why?
| | Wakefulness | 2 | 2015 | 169 | 0.040 |
Why?
| | Animals | 3 | 2024 | 38030 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1322 | 0.040 |
Why?
| | Acute Disease | 1 | 2024 | 1028 | 0.040 |
Why?
| | Subcellular Fractions | 1 | 2021 | 74 | 0.040 |
Why?
| | Citric Acid Cycle | 1 | 2021 | 59 | 0.040 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 51 | 0.040 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 164 | 0.040 |
Why?
| | Motor Activity | 2 | 2015 | 720 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1627 | 0.040 |
Why?
| | Protective Agents | 1 | 2020 | 42 | 0.040 |
Why?
| | Education | 1 | 2020 | 104 | 0.040 |
Why?
| | Proprotein Convertase 9 | 1 | 2020 | 85 | 0.040 |
Why?
| | Stearoyl-CoA Desaturase | 2 | 2010 | 66 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 1304 | 0.040 |
Why?
| | Poisson Distribution | 1 | 2019 | 78 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2019 | 83 | 0.040 |
Why?
| | E-Selectin | 1 | 2018 | 61 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 7155 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 78 | 0.030 |
Why?
| | Probability | 1 | 2019 | 308 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 115 | 0.030 |
Why?
| | Pregnancy | 2 | 2015 | 7180 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2019 | 173 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 138 | 0.030 |
Why?
| | Intra-Abdominal Fat | 1 | 2019 | 100 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2020 | 618 | 0.030 |
Why?
| | Research | 1 | 2020 | 428 | 0.030 |
Why?
| | Leptin | 1 | 2018 | 244 | 0.030 |
Why?
| | Diet | 3 | 2012 | 1271 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3592 | 0.030 |
Why?
| | Biological Transport | 1 | 2017 | 412 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.030 |
Why?
| | Adaptation, Physiological | 2 | 2010 | 569 | 0.030 |
Why?
| | Metabolome | 1 | 2019 | 384 | 0.030 |
Why?
| | Rats | 1 | 2024 | 5592 | 0.030 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 97 | 0.030 |
Why?
| | Diet, Fat-Restricted | 1 | 2015 | 79 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2013 | 2926 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 163 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2018 | 780 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2020 | 699 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1495 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 72 | 0.020 |
Why?
| | Fatty Acids | 1 | 2016 | 450 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2012 | 55 | 0.020 |
Why?
| | Risk | 1 | 2015 | 909 | 0.020 |
Why?
| | Glycerol | 1 | 2012 | 90 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1834 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2015 | 301 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2829 | 0.020 |
Why?
| | Calorimetry, Indirect | 1 | 2010 | 83 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2012 | 242 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 982 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2010 | 42 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 6021 | 0.020 |
Why?
| | Retinoid X Receptor gamma | 1 | 2009 | 4 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 331 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2603 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 54 | 0.020 |
Why?
| | Polysomnography | 1 | 2010 | 234 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 449 | 0.020 |
Why?
| | Bicycling | 1 | 2010 | 120 | 0.020 |
Why?
| | Women's Health | 1 | 2011 | 308 | 0.020 |
Why?
| | Coronary Disease | 1 | 2011 | 381 | 0.020 |
Why?
| | Phospholipids | 1 | 2010 | 211 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1732 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 797 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 981 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 541 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2359 | 0.020 |
Why?
| | Mice | 1 | 2024 | 18329 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 777 | 0.010 |
Why?
| | Genotype | 1 | 2011 | 1833 | 0.010 |
Why?
| | Infant Care | 1 | 1986 | 44 | 0.010 |
Why?
| | Infertility | 1 | 1986 | 55 | 0.010 |
Why?
| | Health Promotion | 1 | 2011 | 774 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 1986 | 160 | 0.010 |
Why?
| | Maternal Health Services | 1 | 1986 | 102 | 0.010 |
Why?
| | Follicular Phase | 1 | 2003 | 38 | 0.010 |
Why?
| | Anaerobic Threshold | 1 | 2003 | 28 | 0.010 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2003 | 85 | 0.010 |
Why?
| | Luteal Phase | 1 | 2003 | 46 | 0.010 |
Why?
| | Catecholamines | 1 | 2003 | 87 | 0.010 |
Why?
| | Contraception | 1 | 1986 | 169 | 0.010 |
Why?
| | Abortion, Induced | 1 | 1986 | 110 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2143 | 0.010 |
Why?
| | Heart Rate | 1 | 2003 | 849 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1986 | 6424 | 0.010 |
Why?
|
|
Perreault's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|